Encouraging results for creatine and minocycline in Parkinson's disease in early
A study by NINDS NET-PD Investigators evaluated whether minocycline creatine el'antibiotico were able to alter the course of Parkinson's disease at an early stage. Participants had been diagnosed with Parkinson's disease for less than 5 years and do not require treatment for the symptoms. The primary endpoint was the change to the scale UPDRS (Unified Parkinson's Disease Rating Scale) from baseline at the time was found sufficient to establish disability symptomatic therapy for Parkinson's disease, or 12 months. A total of 200 patients were randomized in 1:1:1 ratio to receive creatine 10g/die, Minocycline 200 mg or placebo. The futility threshold was defined as a 30% reduction in the progression of the UPDRS scale compared to the placebo arm / DATATOP tocopherol in the study (Deprenyl And Tocopherol Antioxidative Therapy of Parkinsonism). A p value less than or equal to 0.1 index was futility. E 'was observed that neither creatine nor minocycline may be considered futile therapy based on the threshold of futility DATATOP. Tolerability was 91% in the creatine group and 77% in the minocycline group. The most common side effects were: respiratory symptoms (26%), joint pain (19%), nausea (17%). According to the authors, is that the creatine minocycline should be assessed in phase III clinical trials to determine if they are able to change the long-term progression of Parkinson's disease.
NINDS NET-PD Investigators, Neurology 2006; Published online before print
0 comments:
Post a Comment